This website is for UK healthcare professionals only and contains promotional content.

Report an adverse event here
United Kingdom - English

United Kingdom - English

United Kingdom | English

These country specific websites are specifically intended for healthcare professionals in listed countries only.

Europe

Deutschland - DeutschDeutschland - Deutsch España - EspañolEspaña - Español Italia - ItalianoItalia - Italiano United Kingdom - EnglishUnited Kingdom - English

NOTICE: Kyowa Kirin International has agreed a joint venture with Grünenthal GmbH for the Established Medicines portfolio. The new company, KKI NewCo (known as Grünenthal Meds), is responsible for the content on this page. For more information please click here.​

Moventig (naloxegol) logo

MOVENTIG

naloxegol

MOVENTIG is indicated for the treatment of opioid-induced constipation (OIC) in adult patients who have had an inadequate response to laxative(s).1*

MOVENTIG may be used with or without laxatives.1

Adverse Events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk/. Adverse Events should also be reported to Kyowa Kirin International UK NewCo Ltd, known as Grünenthal Meds on +44 (0)1896 664000, email PVUK@grunenthalmeds.com

Click here for Prescribing Information.

Efficacy of MOVENTIG in treating opioid-induced constipation (OIC)2

The efficacy of MOVENTIG has been compared in clinical trials to placebo in treating patients suffering from OIC who have had an inadequate response to laxative therapy.

Pooled data from two randomised, double-blind, placebo-controlled trials were analysed. The patients were experiencing non-cancer pain, aged 18–84 with OIC and had inadequate response to laxatives (defined as concurrent OIC symptoms of at least moderate severity while taking at least one laxative class for a minimum of four days during the pre-study period).1 Patients were randomised to receive MOVENTIG 12.5 mg, 25 mg or placebo. Assessments included response rate, time to first post-dose spontaneous bowel movement, number of spontaneous bowel movements (SBMs), OIC symptoms and patient-reported outcomes over 12 weeks.

Bar chart showing that Moventig (naloxegol) showed lasting relief from the first day of therapy, with a median time to first post-dose spontaneous bowel movement for placebo of 41.1 hours, but 7.5 hours for Moventig (naloxegol) 25mg (p<0.001)
Bar chart showing that Moventig (naloxegol) showed a significantly improved overall response rate compared to placebo
Visualisation that Moventig (naloxegol) 25mg once daily significantly improved OIC related symptoms vs placebo

*Definition of laxative inadequate responder (LIR): In the two weeks prior to first study visit patients had to have reported concurrent OIC symptoms of at least moderate severity while taking at least one laxative class for a minimum of four days during the pre-study period.1

RELATED CONTENT

SUPPORT MATERIALS

Guidelines: NICE and SMC

Recommendations for healthcare professionals on the treatment of opioid-induced constipation (OIC) with naloxegol. Developed by NICE (National Institute for Health and Care Excellence) and the SMC (Scottish Medicines Consortium).

LEARN MORE

SUPPORT MATERIALS

Guidelines: Pathophysiology and management of opioid-induced constipation

Published in the United European Gastroenterology Journal in 2019, view the European expert consensus statement on the pathophysiology and management of opioid-induced constipation.

LINK TO PUBLICATION

MOVENTIG (naloxegol) is indicated for the treatment of opioid-induced constipation (OIC) in adult patients who have had an inadequate response to laxative(s). For advice on the responsible use of opioids to treat pain, please click here

Average:

  • References

    1. MOVENTIG Summary of Product Characteristics.

    2. Tack J, et al. UEG Journal. 2015;3(5):471–480.

    M-N/A-HQ-11-23-0074 March 2024

This website is for healthcare professionals only.

If you are a registered healthcare professional outside the UK please visit the Grünenthal Meds Website

M-GRM-HQ-11-24-0006 May 2025